Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Claudin 18.2 (CLDN18.2)-targeted CAR-T cell and antibody therapies show promise against gastrointestinal cancers, but biomarkers predictive of long-term benefit and therapeutic sensitization strategies are needed. Here we show that proteins carried by circulating extracellular vesicles (EVs) can reflect and influence the efficacy of CLDN18.2-targeted therapies.
Dear editor, Migrasome, an organelle that forms behind migrating cells, is connected to the cell body by a retraction fibre.1 Once released from the retraction fibre, the migrasome transforms into an extracellular vesicle and plays important roles in cell communications,2 development,3 diseases4 and more. So far, it remains unclear whether the bacterial pathogens infection influences migrasome formation, cargo transportation and function.
Abstract The application of immunotherapy in gastrointestinal (GI) cancers remains challenging because of the limited response rate and emerging therapeutic resistance. Combining clinical cohorts, multi-omics study, and functional/molecular experiments, it is found that ANO1 amplification or high-expression predicts poor outcomes and resistance to immunotherapy for GI cancer patients.
Author / Affiliation / Email Search Type Submit to this Journal Review for this Journal Edit a Special Issue Article Menu /ajax/scifeed/subscribe Altmetric share Share announcement Help format_quote Cite thumb_up ... Endorse textsms ... Comment Need Help? Support Find support for a specific problem in the support section of our website. Get Support Feedback Please let us know what you think of our products and services.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
